BACKGROUND: Immune checkpoint inhibitors (ICIs) are successful in treating many cancers but may cause immune-related adverse events. ICI-mediated myocarditis has a high fatality rate with severe cardiovascular consequences. Targeted therapies for ICI myocarditis are currently limited. METHODS: We used a genetic mouse model of PD1 deletion ( MRL/Pdcd1−/− ) along with a novel drug-treated ICI myocarditis mouse model to recapitulate the disease phenotype. We performed single-cell RNA-sequencing, single-cell T-cell receptor sequencing, and cellular indexing of transcriptomes and epitopes on immune cells isolated from MRL and MRL/Pdcd1−/− mice at serial time points. We assessed the impact of macrophage deletion in MRL/Pdcd1−/− mice, then inhibited CXCR3 (C-X-C motif chemokine receptor 3) in ICI-treated mice to assess the therapeutic effect on myocarditis phenotype. Furthermore, we delineated the functional and mechanistic effects of CXCR3 blockade on T-cell and macrophage interactions. We then correlated the results in human single-cell multiomics data from blood and heart biopsy data from patients with ICI myocarditis. RESULTS: Single-cell multiomics demonstrated expansion of CXCL (C-X-C motif chemokine ligand) 9/10+CCR2+ macrophages and CXCR3hi (C-X-C motif chemokine receptor 3 high-expressing) CD8+ (cluster of differentiation) effector T lymphocytes in the hearts of MRL/Pdcd1−/− mice correlating with onset of myocarditis development. Both depletion of CXCL9/10+CCR2+ (C-C motif chemokine receptor) macrophages and CXCR3 blockade, respectively, led to decreased CXCR3hi CD8+ T-cell infiltration into the heart and significantly improved survival. Transwell migration assays demonstrated that the selective blockade of CXCR3 and its ligand, CXCL10, reduced CXCR3+CD8+ T-cell migration toward macrophages, implicating this interaction in T-cell cardiotropism toward cardiac macrophages. Furthermore, cardiomyocyte apoptosis was induced by CXCR3hi CD8+ T cells. Cardiac biopsies from patients with confirmed ICI myocarditis demonstrated infiltrating CXCR3+ T cells and CXCL9+/CXCL10+ macrophages. Both mouse cardiac immune cells and patient peripheral blood immune cells revealed expanded TCRs (T-cell receptors) correlating with CXCR3hi CD8+ T cells in ICI myocarditis samples. CONCLUSIONS: These findings bring forth the CXCR3-CXCL9/10 axis as an attractive therapeutic target for ICI myocarditis treatment, and more broadly as a druggable pathway in cardiac inflammation.
Complement component 1q subcomponent binding protein (C1QBP) is a ubiquitously expressed cellular protein and can be upregulated or activated in a variety of malignant tumors, including those from thyroid, colon and breast, but its role remains unclear in renal cell carcinoma (RCC). In this study, C1QBP knockdown in RCC cell influenced expression of multiple genes associated with cell adhesion, among which L1 cell adhesion molecule (L1CAM) was significantly higher upon a reduction of C1QBP. In turn, cell adhesion and invasion abilities were significantly increased with increased metastasis to lung and liver in vivo. C1QBP may regulate RCC cell adhesion and invasion through influencing the p-GSK3/β-Catenin/L1CAM expression. Over all, our study demonstrated that C1QBP could regulate RCC metastasis by regulating the GSK3/β-Catenin/L1CAM signaling pathway.
Chickens represent a specific case in lipid metabolism that liver is the main site of lipid synthesis. As ovipara, their gut microbiota could be strongly influenced by environment and diets after hatching. The aim of this study is to elucidate the linkage of gut microbiota and fat synthesis in broilers. The broilers were subjected to dietary treatments of combined probiotics (Clostridium butyrate4×108cfu/kg,Bifidobacterium2×108cfu/kg,Lactobacillus plantarum2×108cfu/kg andLactococcus faecalis2×108cfu/kg, PB) and guar gum (1 g/kg, GG). The result showed that dietary supplementation of PB and GG changed the cecal microbiota diversity, altered short chain fatty acids (SCFAs) contents, and suppressed lipogenesis in liver and abdominal fat tissues. In intestinal epithelial cells (IECs), acetate, propionate, and butyrate upregulated the expression of glucagon-like peptide-1 (GLP-1) via MAPK pathways, especially via the ERK and p38 MAPK pathways. GLP-1 suppressed lipid accumulation in primary hepatocytes with the involvement of AMPK/ACC signaling. In conclusion, the result suggests that SCFAs-induced GLP-1 secretion links the regulation of gut microbiome on hepatic lipogenesis in chickens.IMPORTANCE: Intestinal microbes metabolize SCFAs and stimulate intestinal epithelium L cells to produce GLP-1. Recent evidence showed that GLP-1 reduced fat deposition by reducing appetite and increasing satiety. However, how SCFAs stimulate the secretion of GLP-1 and whether GLP-1 directly affects fat metabolism is not clear. Poultry adipocytes have limited ability to produce fat, and 90% of carcass fat is synthesized in the liver. In addition, large intake of feeds easily leads to fatty liver diseases in chickens. The aim of this study is to investigate how SCFAs mediate secretion of GLP-1 and whether GLP-1 could directly affect hepatic deposition in broiler chickens. The hepatic lipogenesis regulated by the intestinal microbiota of chickens is of great significance to the study of intestinal microbiota and fat deposition in poultry, and this work could provide reference for intestinal microorganism and fat metabolism in mammals and humans.